Therapeutic studies with Talazoparib (BMN673, a PARP1/2 inhibitor) significantly increased the frequency of activated NK cells with the enhanced secretion of IFN-γ and TNF-α in the TME of a murine ovarian cancer model [332]. The gene discussed is PARP1; the disease is ovarian cancer.